<p>在過去一週，美國市場保持平穩，但過去一年上漲了 30%，預計年均盈利增長為 16%。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為它們通常反映了管理層對業務前景的信心以及與股東利益的一致性。</p>
<h3>美國內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>優信 (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.3%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>104%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們關於內部持股比例高的快速成長美國公司的 202 只股票的完整列表。</p>
<p>以下是篩選器中一些選擇的預覽。</p>
<h2>Prenetics Global (PRE)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Prenetics Global Limited 是一家健康科學公司，專注於在香港、美國及國際上推動消費者健康，市值約為 3.0847 億美元。</p>
<p><strong>運營：</strong> Prenetics Global Limited 通過其健康科學業務產生收入，旨在提升香港、美國及其他國際市場的消費者健康。</p>
<p><strong>內部持股比例：</strong> 25.6%</p>
<p><strong>收入增長預測：</strong> 年均 53.9%。</p>
<p>Prenetics Global 的增長前景良好，預計年均收入增長 53.9%，超過美國市場平均水平。儘管近期股東稀釋和股價波動，該公司的交易價格顯著低於其估計的公允價值。Prenetics 與 Superpower 的戰略合作增強了其健康產品，而 4000 萬美元的股票回購反映了對未來前景的信心。然而，它面臨着現金流有限和持續淨虧損的挑戰，儘管預計在三年內實現盈利。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Prenetics Global 的表現。</li>
<li>在審查我們最新的估值報告後，Prenetics Global 的股價可能過於悲觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7c17bfca-7281-42b7-b56b-4bcb0840c624/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7c17bfca-7281-42b7-b56b-4bcb0840c624/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 PRE 盈利和收入增長</p>
<h2>Precigen (PGEN)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Precigen, Inc.是一家發現和臨牀階段的生物製藥公司，專注於開發用於免疫腫瘤學、自身免疫疾病和傳染病的基因和細胞療法，市值為 14.6 億美元。</p>
<p><strong>運營：</strong> 公司的收入部分包括生物技術（初創公司），產生了 968 萬美元的收入。</p>
<p><strong>內部持股比例：</strong> 11.9%</p>
<p><strong>收入增長預測：</strong> 年均 39.6%。</p>
<p>Precigen 有望實現增長，預計年均收入增長 39.6%，超過美國市場。儘管 2025 年淨虧損達到 2.5064 億美元和近期股東稀釋，但其交易價格顯著低於估計的公允價值。近期內部活動顯示買入多於賣出，表明對未來前景的信心。預計公司將在三年內實現盈利，支持其高達 48.9% 的預期股本回報率。</p>
<ul>
<li>在這份增長報告中解鎖我們對 Precigen 股票分析的全面見解。</li>
<li>我們的 Precigen 估值報告中的分析暗示其股價可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/ownership-breakdown"/></p>
<p>截至 2026 年 4 月的 PGEN 持股結構</p>
<h2>Diana Shipping (DSX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Diana Shipping Inc.在全球提供航運運輸服務，市值為 2.8933 億美元。</p>
<p><strong>運營：</strong> 該公司從其幹散貨船業務中產生了 2.1354 億美元的收入。</p>
<p><strong>內部持股比例：</strong> 29.3%</p>
<p><strong>收入增長預測：</strong> 年均 13.4%。</p>
<p>儘管財務狀況面臨挑戰，Diana Shipping 顯示出增長潛力，預計盈利將顯著增長，年均 57.6%，超過美國市場。近期的租船協議將增強收入，儘管內部持股活動有限。該公司的交易價格略低於其估計的公允價值，並且股息記錄不穩定。近期的船舶收購和租船表明戰略擴張，但其股本回報率預計將保持在 11.7% 的低水平。</p>
<ul>
<li>點擊探索我們在 Diana Shipping 盈利增長報告中的詳細發現。</li>
<li>我們的估值報告揭示了 Diana Shipping 的股票可能以溢價交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/be860cf4-afc0-4806-b207-b8a9ead47806/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/be860cf4-afc0-4806-b207-b8a9ead47806/chart/ownership-breakdown"/></p>
<p>截至 2026 年 4 月的 DSX 持股結構</p>
<h2>利用機會</h2>
<ul>
<li>在這裏瀏覽 202 個內部持股比例高的快速成長美國公司的完整清單。</li>
<li>對其他選擇感到好奇？稀土金屬是大多數高科技設備、軍事和國防系統以及電動車的原材料。全球競賽正在進行，以確保這些關鍵礦物的供應。搶先發現 32 只最佳稀土金屬股票，這些股票是為數不多的開採這一重要戰略資源的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

UPST

優信

UPSX

<p>在 2026 年 4 月，美國市場保持平穩，但過去一年上漲了 30%，預計收益將以每年 16% 的速度增長。高內部持股的成長型公司受到關注，包括優信（35.7% 的持股比例，74.1% 的增長）、Upstart Holdings（12.8% 的持股比例，53.6% 的增長）和 Precigen（11.9% 的持股比例，68.4% 的增長）。Prenetics Global 和 Diana Shipping 也因其增長潛力而受到關注，儘管面臨挑戰。文章強調了內部持股作為商業前景信心指標的重要性</p>

<p>In the last week, the United States market has stayed flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often reflect management's confidence in their business prospects and alignment with shareholder interests.</p>
<div class="lb-trans"><p>在過去一週，美國市場保持平穩，但過去一年上漲了 30%，預計年均盈利增長為 16%。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為它們通常反映了管理層對業務前景的信心以及與股東利益的一致性。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.3%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>104%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>優信 (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.3%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>104%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 202 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們關於內部持股比例高的快速成長美國公司的 202 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的預覽。</p>
</div><h2>Prenetics Global (PRE)</h2>
<div class="lb-trans"><h2>Prenetics Global (PRE)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Prenetics Global Limited is a health sciences company that focuses on advancing consumer health in Hong Kong, the United States, and internationally, with a market cap of approximately $308.47 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prenetics Global Limited 是一家健康科學公司，專注於在香港、美國及國際上推動消費者健康，市值約為 3.0847 億美元。</p>
</div><p><strong>Operations:</strong> Prenetics Global Limited generates revenue through its health sciences operations aimed at enhancing consumer health across Hong Kong, the United States, and other international markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> Prenetics Global Limited 通過其健康科學業務產生收入，旨在提升香港、美國及其他國際市場的消費者健康。</p>
</div><p><strong>Insider Ownership:</strong> 25.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 25.6%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 53.9% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 53.9%。</p>
</div><p>Prenetics Global is positioned for growth with a forecasted 53.9% annual revenue increase, surpassing the US market average. Despite recent shareholder dilution and volatility in share price, the company trades significantly below its estimated fair value. Prenetics' strategic partnership with Superpower enhances its health offerings, while a $40 million share buyback reflects confidence in future prospects. However, it faces challenges such as limited cash runway and ongoing net losses despite expected profitability within three years.</p>
<div class="lb-trans"><p>Prenetics Global 的增長前景良好，預計年均收入增長 53.9%，超過美國市場平均水平。儘管近期股東稀釋和股價波動，該公司的交易價格顯著低於其估計的公允價值。Prenetics 與 Superpower 的戰略合作增強了其健康產品，而 4000 萬美元的股票回購反映了對未來前景的信心。然而，它面臨着現金流有限和持續淨虧損的挑戰，儘管預計在三年內實現盈利。</p>
</div><ul>
<li>Get an in-depth perspective on Prenetics Global's performance by reading our analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Prenetics Global's share price might be too pessimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Prenetics Global 的表現。</li>
<li>在審查我們最新的估值報告後，Prenetics Global 的股價可能過於悲觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7c17bfca-7281-42b7-b56b-4bcb0840c624/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/7c17bfca-7281-42b7-b56b-4bcb0840c624/chart/earnings-and-revenue-growth"/></p>
<p>PRE Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 PRE 盈利和收入增長</p>
</div><h2>Precigen (PGEN)</h2>
<div class="lb-trans"><h2>Precigen (PGEN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.46 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Precigen, Inc.是一家發現和臨牀階段的生物製藥公司，專注於開發用於免疫腫瘤學、自身免疫疾病和傳染病的基因和細胞療法，市值為 14.6 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment includes Biotechnology (Startups), generating $9.68 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分包括生物技術（初創公司），產生了 968 萬美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 11.9%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 11.9%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 39.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 39.6%。</p>
</div><p>Precigen is poised for growth, with revenue expected to increase 39.6% annually, outpacing the US market. Despite a substantial net loss of US$250.64 million in 2025 and recent shareholder dilution, it trades significantly below estimated fair value. Insider activity shows more buying than selling recently, indicating confidence in its future prospects. The company is forecasted to achieve profitability within three years, supported by a high anticipated return on equity of 48.9%.</p>
<div class="lb-trans"><p>Precigen 有望實現增長，預計年均收入增長 39.6%，超過美國市場。儘管 2025 年淨虧損達到 2.5064 億美元和近期股東稀釋，但其交易價格顯著低於估計的公允價值。近期內部活動顯示買入多於賣出，表明對未來前景的信心。預計公司將在三年內實現盈利，支持其高達 48.9% 的預期股本回報率。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Precigen stock in this growth report.</li>
<li>The analysis detailed in our Precigen valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份增長報告中解鎖我們對 Precigen 股票分析的全面見解。</li>
<li>我們的 Precigen 估值報告中的分析暗示其股價可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/ownership-breakdown"/></p>
<p>PGEN Ownership Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 PGEN 持股結構</p>
</div><h2>Diana Shipping (DSX)</h2>
<div class="lb-trans"><h2>Diana Shipping (DSX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Diana Shipping Inc. provides shipping transportation services globally with a market cap of $289.33 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Diana Shipping Inc.在全球提供航運運輸服務，市值為 2.8933 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $213.54 million from its dry-bulk vessels segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其幹散貨船業務中產生了 2.1354 億美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 29.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 29.3%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 13.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 13.4%。</p>
</div><p>Diana Shipping shows potential for growth despite a challenging financial position, with earnings expected to grow significantly at 57.6% per year, outpacing the US market. Recent charter agreements are set to bolster revenue, although insider ownership activity is limited. The company trades slightly below its estimated fair value and has an unstable dividend track record. Recent vessel acquisitions and charters indicate strategic expansion, but its return on equity is forecasted to remain low at 11.7%.</p>
<div class="lb-trans"><p>儘管財務狀況面臨挑戰，Diana Shipping 顯示出增長潛力，預計盈利將顯著增長，年均 57.6%，超過美國市場。近期的租船協議將增強收入，儘管內部持股活動有限。該公司的交易價格略低於其估計的公允價值，並且股息記錄不穩定。近期的船舶收購和租船表明戰略擴張，但其股本回報率預計將保持在 11.7% 的低水平。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Diana Shipping's earnings growth report.</li>
<li>Our valuation report unveils the possibility Diana Shipping's shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Diana Shipping 盈利增長報告中的詳細發現。</li>
<li>我們的估值報告揭示了 Diana Shipping 的股票可能以溢價交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/be860cf4-afc0-4806-b207-b8a9ead47806/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/be860cf4-afc0-4806-b207-b8a9ead47806/chart/ownership-breakdown"/></p>
<p>DSX Ownership Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 DSX 持股結構</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Navigate through the entire inventory of 202 Fast Growing US Companies With High Insider Ownership here.</li>
<li>Curious About Other Options? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏瀏覽 202 個內部持股比例高的快速成長美國公司的完整清單。</li>
<li>對其他選擇感到好奇？稀土金屬是大多數高科技設備、軍事和國防系統以及電動車的原材料。全球競賽正在進行，以確保這些關鍵礦物的供應。搶先發現 32 只最佳稀土金屬股票，這些股票是為數不多的開採這一重要戰略資源的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

2026 年 4 月擁有內部持股的頂級增長公司